The University of Southampton
University of Southampton Institutional Repository

The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications

The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications
The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications
Splenic marginal zone lymphoma (SMZL) is a rare, predominantly indolent B-cell lymphoma constituting fewer than 2% of lymphoid neoplasms. However, around 30% of patients have a shorter survival despite currently available treatments and the prognosis is especially poor for the 5–15% of cases that transform to a large cell lymphoma. Mounting evidence suggests that the molecular pathogenesis of SMZL is critically shaped by microenvironmental triggering and cell-intrinsic aberrations. Immunogenetic investigations have revealed biases in the immunoglobulin gene repertoire, indicating a role of antigen selection. Furthermore, cytogenetic studies have identified recurrent chromosomal abnormalities such as deletion of the long arm of chromosome 7, though specific disease-associated genes remain elusive. Our knowledge of SMZL’s mutational landscape, based on a limited number of cases, has identified recurring mutations in KLF2, NOTCH2, and TP53, as well as genes clustering within vital B-cell differentiation pathways
Lymphoma, biomarkers, clinical outcome, genomics, haematology, splenic marginal zone lymphoma, therapeutic targets
2692-3114
877-901
Mirandari, Amatta
b8640936-4b35-47c5-b6f1-f4d81ab6e2f6
Parker, Helen
33e0cd81-d45f-49bc-9539-09345d79d895
Ashton-Key, Margaret
5111ac18-7d4f-4ef0-9c71-0a44c37aaed4
Stevens, Benjamin
cdb35be2-947a-4acd-bddb-950f130757cd
Walewska, Renata
8c1c279c-2c6b-4ede-ad1e-6daaa913d5a0
Stamatopoulos, Kostas
04185c9f-28ac-4693-bcff-4b6f2081de5c
Bryant, Dean
10ed83e8-8080-4d9c-bba5-df9d4eec3a10
Oscier, David G.
b6fcba46-33b2-4a3a-a71c-6ab71eb854bc
Gibson, Jane
855033a6-38f3-4853-8f60-d7d4561226ae
Strefford, Jonathan C.
3782b392-f080-42bf-bdca-8aa5d6ca532f
Mirandari, Amatta
b8640936-4b35-47c5-b6f1-f4d81ab6e2f6
Parker, Helen
33e0cd81-d45f-49bc-9539-09345d79d895
Ashton-Key, Margaret
5111ac18-7d4f-4ef0-9c71-0a44c37aaed4
Stevens, Benjamin
cdb35be2-947a-4acd-bddb-950f130757cd
Walewska, Renata
8c1c279c-2c6b-4ede-ad1e-6daaa913d5a0
Stamatopoulos, Kostas
04185c9f-28ac-4693-bcff-4b6f2081de5c
Bryant, Dean
10ed83e8-8080-4d9c-bba5-df9d4eec3a10
Oscier, David G.
b6fcba46-33b2-4a3a-a71c-6ab71eb854bc
Gibson, Jane
855033a6-38f3-4853-8f60-d7d4561226ae
Strefford, Jonathan C.
3782b392-f080-42bf-bdca-8aa5d6ca532f

Mirandari, Amatta, Parker, Helen, Ashton-Key, Margaret, Stevens, Benjamin, Walewska, Renata, Stamatopoulos, Kostas, Bryant, Dean, Oscier, David G., Gibson, Jane and Strefford, Jonathan C. (2024) The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications. Exploration of Targeted Anti-Tumor Therapy, 5 (5), 877-901. (doi:10.37349/etat.2024.00253).

Record type: Review

Abstract

Splenic marginal zone lymphoma (SMZL) is a rare, predominantly indolent B-cell lymphoma constituting fewer than 2% of lymphoid neoplasms. However, around 30% of patients have a shorter survival despite currently available treatments and the prognosis is especially poor for the 5–15% of cases that transform to a large cell lymphoma. Mounting evidence suggests that the molecular pathogenesis of SMZL is critically shaped by microenvironmental triggering and cell-intrinsic aberrations. Immunogenetic investigations have revealed biases in the immunoglobulin gene repertoire, indicating a role of antigen selection. Furthermore, cytogenetic studies have identified recurrent chromosomal abnormalities such as deletion of the long arm of chromosome 7, though specific disease-associated genes remain elusive. Our knowledge of SMZL’s mutational landscape, based on a limited number of cases, has identified recurring mutations in KLF2, NOTCH2, and TP53, as well as genes clustering within vital B-cell differentiation pathways

Text
2024_Mirandari_Strefford_SMZL_Genomics_Review_1002253 - Version of Record
Available under License Creative Commons Attribution.
Download (4MB)

More information

Accepted/In Press date: 8 May 2024
Published date: 23 July 2024
Keywords: Lymphoma, biomarkers, clinical outcome, genomics, haematology, splenic marginal zone lymphoma, therapeutic targets

Identifiers

Local EPrints ID: 494976
URI: http://eprints.soton.ac.uk/id/eprint/494976
ISSN: 2692-3114
PURE UUID: 02437f86-f202-4ec4-9a2a-1d9527ec4b1d
ORCID for Helen Parker: ORCID iD orcid.org/0000-0001-8308-9781
ORCID for Dean Bryant: ORCID iD orcid.org/0000-0003-3163-608X
ORCID for Jane Gibson: ORCID iD orcid.org/0000-0002-0973-8285
ORCID for Jonathan C. Strefford: ORCID iD orcid.org/0000-0002-0972-2881

Catalogue record

Date deposited: 24 Oct 2024 16:44
Last modified: 26 Oct 2024 01:46

Export record

Altmetrics

Contributors

Author: Amatta Mirandari
Author: Helen Parker ORCID iD
Author: Margaret Ashton-Key
Author: Benjamin Stevens
Author: Renata Walewska
Author: Kostas Stamatopoulos
Author: Dean Bryant ORCID iD
Author: David G. Oscier
Author: Jane Gibson ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×